Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 50%Low 1 · 16.7%Moderate 1 · 16.7%High 1 · 16.7%

Change in symptom severity at 3 weeks (secondary efficacy outcome) · Adults (aged 18 and over) with acute mania

1 finding from 1 review

Valproate for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 57 participants
Very low

Change in symptom severity at 3 weeks (secondary efficacy outcome) · Adults (aged 18 and over) with acute mania

1 finding from 1 review

Valproate for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 826 participants
High

Change in symptom severity at 3 weeks (secondary efficacy outcome) · Adults (aged 18 and over) with acute mania

1 finding from 1 review

Valproate for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 907 participants
Moderate

Change in symptom severity at 3 weeks (secondary efficacy outcome) · Children and adolescents with acute mania

1 finding from 1 review

Valproate for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 144 participants
Very low

Change in symptom severity at 5 ‐ 12 weeks (secondary efficacy outcome) · Children and adolescents with acute mania

1 finding from 1 review

Valproate for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 228 participants
Low

Change in symptom severity of mania rating scale at 8 weeks (secondary efficacy outcome) · Children and adolescents with acute mania

1 finding from 1 review

Valproate for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 190 participants
Very low